FY2025 Impact Report
Now Live: The Digital FY25 Impact Report
The Lymphoma Coalition FY25 Impact Report is now available in an enhanced digital format, providing an interactive snapshot of the Coalition’s key achievements and impact over the past fiscal year.
Throughout FY25, Lymphoma Coalition collaborated across its global network to strengthen evidence-based research, amplify patient and Member voices, and promote equitable access to care. The digital report highlights these achievements through interactive features and key insights that reflect the Coalition’s ongoing commitment to improving outcomes for those affected by lymphoma and CLL.
Click below to view the new digital version
For those seeking further insight, the full detailed report contains additional outcomes from across Lymphoma Coalition’s programmes and initiatives. It is available for download in both A4 and Letter formats below.
View Past Reports
FY2024 Year in Review
FY2024 Year in Review
Lymphoma Coalition has recently released the FY24 Year in Review which provides a detailed overview of the practical projects and collaborative efforts we undertook in FY24.
From research advancements to awareness initiatives, it encapsulates the efforts of our global community throughout the fiscal year.
The Report is available for download in both A4 and Letter sizes.
FY2023 Year in Review
FY2023 Year in Review
Lymphoma Coalition has recently released the FY23 Year in Review which provides a detailed overview of the practical projects and collaborative efforts we undertook in FY23. From research advancements to awareness initiatives, it encapsulates the efforts of our global community throughout the fiscal year.
Lymphoma Coalition Financial Statements
Lymphoma Coalition was incorporated as a not for profit organisation in Canada in 2010, corporation number 756514-3. If you would like more information, please contact us.
Lymphoma Coalition is formally audited each year, in adherence to corporate by-laws, and the audited statements are presented to and approved by members at the Annual General Meeting. Below are the most recent audited statements.
Lymphoma Coalition Europe Funding
Lymphoma Coalition Europe (LCE) was 100% funded by pharmaceutical companies in Fiscal Year 2024 and received sponsorship from nine (9) companies:
- Incyte
- Ipsen
- Janssen
- Lilly
- Novartis
- SERB
- SOBI
- Roche (€110,500 – 27% of total funding)
- Takeda
None of these companies funded 50% or more of LCE’s funding.
Lymphoma Coalition policies and procedures about how we work with industry were followed, which can be read below.
Lymphoma Coalition Supporters
We are grateful to our sponsors for their caring and support, for without them giving back to the lymphoma community, we would not be able to work towards our mission and vision.
Our supporters play a key role in the work LC undertakes. Through their support, LC is able to:
- Share best practices among its members;
- Provide consistent as well as reliable current information including statistics on the different lymphomas including chronic lymphocytic leukaemia;
- As a larger community of lymphoma patient organisations, raise awareness about lymphomas through activities such as World Lymphoma Awareness Day and the Global Patient Survey;
- Capacity building support for member organisations.
Sponsorship Benefit
Be a part of a global voice supporting patients with lymphoma worldwide.
For more information on sponsorship opportunities, contact Lorna Warwick, Chief Executive Officer.
